The Université libre de Bruxelles is a French-speaking research university in Brussels, Belgium. ULB is one of the two institutions, which trace their origins to the Free University of Brussels, founded in 1834 by Belgian lawyer Pierre-Théodore Verhaegen.

During the past decade, Université Libre de Bruxelles conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 3 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Université Libre de Bruxelles" #1 sponsor was "Grifols Therapeutics LLC" with 2 trials, followed by "Lung Biotechnology PBC" with 2 trials sponsored, "Codman & Shurtleff" with 1 trials sponsored, "European Friedreich's Ataxia Consortium for Translational Studies" with 1 trials sponsored and "Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Université Libre de Bruxelles" #1 collaborator was "Instituto Grifols, S.A." with 2 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Université Libre de Bruxelles" are "Pulmonary Arterial Hypertension" (2 trials), "Acute-On-Chronic Liver Failure" (1 trials), "Decompensated Cirrhosis and Ascites" (1 trials), "Diabetes Mellitus, Type 1" (1 trials) and "Friedreich's Ataxia" (1 trials). Many other conditions were trialed in "Université Libre de Bruxelles" in a lesser frequency.

Most popular intervention types in "Université Libre de Bruxelles" are "Drug" (5 trials), "Other" (3 trials), "Device" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Beraprost Sodium Modified Release" (2 trials), "Albutein 20% Injectable Solution" (1 trials), "Anti-Human Thymocyte Immunoglobulin, Rabbit" (1 trials), "Control group" (1 trials) and "Inhaled treprostinil" (1 trials). Other intervention names were less common.

The vast majority of trials in "Université Libre de Bruxelles" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Université Libre de Bruxelles". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Université Libre de Bruxelles, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Université Libre de Bruxelles, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".